Houston ramps up ivermectin campaign amid rising hantavirus concerns
2026-05-09
Hantavirus anxiety is giving an old controversy fresh oxygen. In Houston, a Texas physician who drew discipline for promoting ivermectin during the coronavirus emergency is again urging patients to consider the antiparasitic drug, now floated as a hedge against rodent‑borne infection.
This renewed push looks less like innovation than repetition. Infectious‑disease specialists stress that hantavirus pulmonary syndrome is a viral illness with no approved antiviral cure and certainly no evidence that ivermectin alters pathogenesis, viral replication, or mortality. Regulatory agencies still classify ivermectin for humans as a treatment for onchocerciasis and strongyloidiasis, not as a broad‑spectrum antiviral, and professional societies warn that off‑label promotion without randomized controlled trial data undermines evidence‑based medicine.
The real story is not one doctor but a vacuum of trust. Public health officials report an uptick in online chatter that links hantavirus fears to old coronavirus debates, recycling claims about “early treatment protocols” and “suppressed cures” while offering no peer‑reviewed data on viral load, neutralizing antibodies, or clinical endpoints. Hospital leaders in Houston say they are preparing for confused patients demanding prescriptions, while toxicologists quietly brace for another wave of overdose calls, a reminder that medical misinformation rarely stays confined to one outbreak.
Loading...
